Form 4: Director Lynne Chou O'Keefe Reports Vesting of Restricted Stock Units in Hims & Hers Health, Inc.

Lynne Chou O'Keefe, a director of Hims & Hers Health, Inc., reported the vesting of 19,707 Restricted Stock Units (RSUs) on June 6, 2024, convertible to Class A Common Stock.

Summary

• On June 6, 2024, Lynne Chou O'Keefe, a director of Hims & Hers Health, Inc. (HIMS), had 19,707 Restricted Stock Units (RSUs) vest.
• These RSUs represent a contingent right to receive one share of Class A Common Stock for each RSU.
• The vesting occurred on the date of the company's 2024 annual stockholders meeting.
• The RSUs were granted to the reporting person and will vest on the earlier of the date of the 2024 annual meeting of stockholders or June 15, 2024.
• Following the transaction, Ms. O'Keefe directly owns 19,707 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The document reflects a neutral event (vesting of RSUs) that is part of a standard compensation package. It indicates alignment of the director's interests with shareholders, which is generally viewed positively.

Positives

• The vesting of RSUs aligns the director's interests with those of the shareholders.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common for publicly traded companies. It provides transparency regarding the equity holdings of company directors.

Comparison to Industry Standards

• Equity compensation, such as RSUs, is a standard practice in the technology and healthcare industries to incentivize and retain key personnel.
• Companies like Teladoc Health and GoodRx also utilize RSUs as part of their compensation packages for directors and executives.
• The vesting schedules and terms of these RSUs are generally aligned with industry norms, focusing on long-term value creation.

Stakeholder Impact

• The vesting of RSUs has a minor dilutive effect on existing shareholders.
• It aligns the director's interests with the long-term performance of the company, which can benefit shareholders.

Key Dates